What Acurx Pharmaceuticals, Inc. does.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum (“GPSS®”) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (“DNA”) polymerase IIIC (“pol IIIC”), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Our research and development (“R&D”) pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (“C. difficile ”), methicillin-resistant Staphylococcus aureus (“MRSA”), vancomycin resistant Enterococcus (“VRE”) and drug-resistant Streptococcus pneumoniae (“DRSP”) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).

These bacterial targets are listed as priority pathogens by the World Health Organization (“WHO”), the United States (“U.S.”) Centers for Disease Control and Prevention (“CDC”) and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance (“AMR”) as identified by the WHO, CDC and FDA.

Revenue and profit, by fiscal year.

More on ACXP.

• Acurx Pharmaceuticals, Inc. summary
• Acurx Pharmaceuticals, Inc. financial statements
• Acurx Pharmaceuticals, Inc. key metrics
• Acurx Pharmaceuticals, Inc. health scores and style box
• Acurx Pharmaceuticals, Inc. earnings
• Acurx Pharmaceuticals, Inc. dividends
• Acurx Pharmaceuticals, Inc. valuation
• Acurx Pharmaceuticals, Inc. ownership and insiders
• Acurx Pharmaceuticals, Inc. peers

Figures from Acurx Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.